Benitec Biopharma Limited (BNTC) Quote

BNTC under $15

SOFI SoFi Technologies, Inc. 25.139M

BNTC under $10

BNTC new 52 week high

Little monster today

BNTC: MONSTER thanks for the heads-up on this one!!! (Tossing some bucks at it right now, Dude!! Almost forget about it!!)

BNTC up A/H 3.84

BNTC: $68 price target, by a number of stock prognosticators; the MYSTERY PLAY of the DAY, & for weeks ahead.
https://beststocks.com/title-trading-opportunities-and-consideration/

wish i had picked this up this morning, wow, what a run!

BNTC 1 for 7
Of course it took off

1 for 17 reverse split 7/26/23

$BNTC - Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy| 06/26/2023
Up 8.3% Pre-Market/ Current Price $0.21

30k @ .23, nice pps for any term hold

This is about to reverse on shorts. I covered my short here.. way too risky. Going in long now for $1-2 ez money

Gettin closer

Got feelins for .56

No paper trading here

paper trading doesn't count!

Second chance right here

NEWS
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
Dosing of the first subject with BB-301 is expected in the second half of 2023, following the rollover of subjects currently enrolled in the ongoing Natural History (NH) study
HAYWARD, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BB-301, its silence and replace gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia.

Oculopharyngeal Muscular Dystrophy (OPMD) is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. OPMD patients lose the ability to swallow liquids and solids, resulting in chronic malnutrition, aspiration, and fatal episodes of aspiration pneumonia. Currently, there are no approved therapeutic agents for the treatment of OPMD.

“The FDA’s clearance of our IND for BB-301 is a significant milestone for OPMD patients and for Benitec as a Company,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “The clearance of BB-301 for clinical use represents the first potential treatment for these frequently debilitating and possibly fatal symptoms of OPMD.”

Subjects from Benitec’s ongoing NH study will be eligible for rollover onto the Phase 1b/2a clinical study of BB-301 for the treatment of OPMD-related Dysphagia after 6 months of baseline data collection. Following a 1-day dosing procedure for BB-301, each study subject will be evaluated for the same radiographic and clinical outcome measures as were evaluated during the NH study, including quantitative radiographic swallowing studies to facilitate objective assessments of swallowing safety, swallowing efficiency, and functional performance of the pharyngeal muscles underlying the OPMD-related Dysphagia. Currently, there are 13 subjects enrolled into the NH study, with each subject having the potential to rollover onto the Phase 1b/2a clinical dosing study for BB-301. Interim safety and efficacy data is expected to become available from the BB-301 Phase 1b/2a study approximately every 90 days following the dosing of each subject.

About BB-301

BB-301 is a novel, modified AAV9 capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1. The two siRNAs are modeled into microRNA backbones to silence expression of faulty mutant PABPN1, while allowing expression of the codon-optimized PABPN1 to replace the mutant with a functional version of the protein. We believe BB-301’s silence and replace strategy is uniquely positioned for the treatment of OPMD by halting mutant expression while providing a functional replacement protein.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.

Forward Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release include forward-looking statements, including statements regarding Benitec's plans to develop and commercialize its product candidates, the timing of the initiation and completion of pre-clinical and clinical trials, the timing of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing, and other forward-looking statements.

These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; the Company's ability to protect and enforce its patents and other intellectual property rights; the Company's dependence on its relationships with its collaboration partners and other third parties; the efficacy or safety of the Company's products and the products of the Company's collaboration partners; the acceptance of the Company's products and the products of the Company's collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; the Company's ability to satisfy its capital needs through increasing its revenue and obtaining additional financing; given market conditions and other factors, including our capital structure; our ability to continue as a going concern; the length of time over which the Company expects its cash and cash equivalents to be sufficient to execute on its business plan; the impact of COVID-19, the disease caused by the SARS-CoV-2 virus, which may adversely impact the Company's business and pre-clinical and future clinical trials; the impact of local, regional, and national and international economic conditions and events; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

William Windham
VP, Solebury Strategic Communications
Phone: 646-378-2946
Email: wwindham@soleburystrat.com

https://www.globenewswire.com/newsroom/ti?nf=ODg2Mzk0MiM1NjYzMjYxIzIyNTEwNzE=
https://ml.globenewswire.com/media/NTk5YjFkNjEtMDE1Yy00N2ZmLWE5NzgtODQ2NjgzNzhkZjNhLTEyNjI2MjQ=/tiny/Benitec-Biopharma-Inc-.png

Source: Benitec Biopharma Inc.
© 2023 GlobeNewswire, Inc.

Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Nasdaq

DAILY ADVANCERS
OTCQX Best Market Logo
BCHG
+ 39.78 %
OTCQX Best Market Logo
NKOSF
+ 19.12 %
OTCQX Best Market Logo
CTLHF
+ 16.27 %
OTCQX Best Market Logo
BLSTF
+ 15.83 %
OTCQX Best Market Logo
VSQTF
+ 15.45 %

Get the best-in-class trading platforms that keep getting better with thinkorswim®.
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.

Gotta bust .32

BNTC received a strong buy rating from 2 analyst:
https://www.nasdaq.com/market-activity/stocks/bntc/analyst-research

Quite a few tutes own it:
https://finance.yahoo.com/quote/BNTC/holders?p=BNTC


so....why is it still floundering in the toilet @$.20 especially with IND slotted for April? What gives?

nobody on ihub cares unless its spoonfed to them. one look at the weekly tells a story. what happened at the end of 2002

Glad I bought.2297,it’s going crazy in after mkt ,nhod

Last 5 years,They let it run,1X per year(around this date),with it moving 5%on just a few $hundred,this might be it, worth a swing to see for me

8Xs ave volume,buyout coming?something is coming!!

Has until September 5th to regain compliance

Bid for some.

BNTC

Break $2 and we can run

Today is day 3 on this play

BNTC $4.25 Its Ready Chart —-> https://stockcharts.com/h-sc/ui?s=bntc

Breakout Watch Tomorrow $$$

ANY NEWS?

Ok

ok

Wow

Joebotts, here's a fascinating fact. Unlike Regen, Benitec actually has a real life management team with a real life CEO and real life pipeline along with many real employees. BNTC is not a ghost company like Regen.

Gee wilikers ok

I'll educate you, yet again. There is no longer a connection. Regen licensed $BNTC's gene silencing tech but like everything Regen does, it squandered it.

A simple google search would have given you your answer. https://www.biospace.com/article/releases/regen-biopharma-licenses-cancer-gene-silencing-technology-from-benitec-inc-/

You are welcome, yet again.

What is the connection to RGBP ..

* * $BNTC Video Chart 03-23-2021 * *

Link to Video - click here to watch the technical chart video

So strong. Buy!

Nice

Great news...and the insiders are dumping.

Benitec is engaged in providing gene silencing therapies, combining RNA interference with gene therapy.

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today
5:20 am ET March 23, 2021 (Benzinga) Print
The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday.

What Happened: Benitec shares had closed at $3.19 on Monday.

The surge follows Morgan Stanley (NYSE: MS) disclosing in a filing with the U.S. Securities and Exchange Commission after the markets closed on Monday that it had increased its stake by about 5.2% in the Australian biotechnology company.

Morgan Stanley disclosed in the 13G filing it now owned 249,174 shares in Benitec, compared to about 13,100 earlier.

Benitec is engaged in providing gene silencing therapies, combining RNA interference with gene therapy.

$BNTC is screaming for the top after a Schedule 13D filing with the SEC showed that Morgan Stanley has taken a large stake. https://cnafinance.com/bntc-stock-benitic-biopharma-attracts-morgan-stanley/

Sht day what’s up

Moving up a little by little

Yes sir. I posted this morning and this company is legit!!